ライフサイエンスコーパス: ambulatory patient

1 xis may be appropriate for some HIV-infected ambulatory patients.

2 trials and in reducing ischemic episodes in ambulatory patients.

3 ucose meter system in critical care/hospital/ambulatory patients.

4 on medical outcomes other than mortality in ambulatory patients.

5 al epidemics and has not been examined among ambulatory patients.

6 about how to approach PPI de-prescribing in ambulatory patients.

7 WiFi-enabled iPod to obtain ECGs (iECGs) in ambulatory patients.

8 reatment of early neurologic Lyme disease in ambulatory patients.

9 cycline for early neurologic Lyme disease in ambulatory patients.

10 o 15 years, improved the conditions of the 3 ambulatory patients.

11 DESIGN Family study of ambulatory patients.

12 ated with higher cardiovascular mortality in ambulatory patients.

13 r pharmacological stress echo in a cohort of ambulatory patients.

14 n this nationwide sample of hospitalized and ambulatory patients.

15 undergoing minor surgical procedures and 562 ambulatory patients.

16 ry 30 minutes of time spent scheduled to see ambulatory patients.

17 limited and not relevant to the majority of ambulatory patients.

18 , has been successful in normal subjects and ambulatory patients.

19 The sample consists of US ambulatory patients 17 years or older with at least 3 ye

20 alized patients, (2) 0.80 for noncholestatic ambulatory patients, (3) 0.87 for PBC patients, and (4)

21 is approved in the USA for the treatment of ambulatory patients (4-5 years) with Duchenne muscular d

22 Of 10 ambulatory patients, 5 died from untreated VF, 4 had car

23 mpared with general anesthesia in previously ambulatory patients 50 years of age or older who were un

24 Of 6441 ambulatory patients (79 percent of all ED visits) who we

25 We evaluated the quadriceps muscles in 34 ambulatory patients and 13 healthy controls, at 6-to 12-

26 A total of 3045 patents (49 percent of ambulatory patients and 37 percent of total ED visits) w

27 5 patients with HIV/AIDS from two sites: 148 ambulatory patients and 47 patients who had been recentl

28 heart failure (HF), affecting ~30% of stable ambulatory patients and 50% patients with acute decompen

29 r improving pancreatic tail visualization in ambulatory patients and is superior to the use of water

30 Fifteen studies included ambulatory patients, and 9 exclusively enrolled from an

31 nous nutritional support of hospitalized and ambulatory patients, and that pharmaceutical manufacture

32 Although many ambulatory patients appear to have nonurgent conditions

33 er, overall patterns of antibiotic use among ambulatory patients are not well understood.

34 Telehealth can be safely used in selected ambulatory patients as a substitute for the standard pos

35 amlanivimab and etesevimab (700/1400 mg) for ambulatory patients at high risk for severe COVID-19.

36 Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to

37 In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection,

38 h severe limitation was less common than for ambulatory patients enrolled in INTERMACS before ventric

39 Thus, records of 456 ambulatory patients evaluated for Cbl deficiency at a st

40 In ambulatory patients evaluated for obstructive coronary d

41 The role exercise testing plays in selecting ambulatory patients for heart transplantation is emphasi

42 ngle-lead iECG with remote interpretation in ambulatory patients >/=65 years of age at increased risk

43 nt clinical status and virologic outcomes in ambulatory patients >=12 years old, with mild-to-moderat

44 Ambulatory patients >=6 months of age meeting a common M

45 in the case group were well-functioning and ambulatory patients having COPD as determined by their h

46 ging from 5.1% for the 2097 hospitalized and ambulatory patients (in six study cohorts) to 36.5% for

47 Long-term statin administration in ambulatory patients is associated with a reduced risk of

48 Antibiotic use in ambulatory patients is decreasing in the United States.

49 lements of primary care in their approach to ambulatory patients is unknown.

50 laide, Australia, among overweight and obese ambulatory patients (N = 150) with symptomatic atrial fi

51 d phase 2/3 trial at 49 US centers including ambulatory patients (N = 613) who tested positive for SA

52 (Se)/specificities (Sp) for diagnosis in an ambulatory patient of obstructive coronary disease (> or

53 Primary care physicians with busier ambulatory patient practices delivered lower-quality dia

54 clusion: Primary care physicians with busier ambulatory patient practices delivered lower-quality dia

55 iotic prescriptions and clinical outcomes in ambulatory patients presenting at outpatient facilities

56 Adult, nonpregnant, HIV-positive, ambulatory patients presenting for any HIV care, includi

57 Consecutive ambulatory patients presenting for care.

58 Ambulatory patients presenting with signs or symptoms of

59 inical trial (Targeted Thromboprophylaxis in Ambulatory Patients Receiving Anticancer Therapies [TARG

60 Ambulatory patients receiving systemic cancer therapy ar

61 We retrospectively studied 181 ambulatory patients referred to the Saint Louis Universi

62 Ambulatory patients reported varied experiences after DT

63 ontinued medications represents an important ambulatory patient safety concern.

64 Most ambulatory patients seek care in an ED because of worris

65 An independent group of 18 ambulatory patients served as a control group.Methods: L

66 Single measurements in 27 ambulatory patients showed elevated CK (953 U/l; 562 to

67 study, we analyzed data on hospitalized and ambulatory patients spanning 22 years (1985-2006) and 10

68 In the ambulatory patient, the main goal is to maximize functio

69 e across the spectrum of heart failure, from ambulatory patients to those in cardiogenic shock or und

70 ed from February 1 to August 31, 2015, among ambulatory patients undergoing breast reconstruction at

71 n order to direct antiemetic prophylaxis for ambulatory patients undergoing office-based anesthesia.

72 A total of 10 660 COVID-19-positive ambulatory patients were eligible, and 9378 (88.0%) had

73 Among ambulatory patients who had heart failure with a reduced

74 Participants were ambulatory patients who received a prescription from a d

75 The study population consisted of 1552 ambulatory patients who underwent pharmacological (752 d

76 ed Kingdom among a prospective cohort of 425 ambulatory patients with a histologically confirmed diag

77 sses were used to obtain 68 recordings in 44 ambulatory patients with a history of intermittent exotr

78 acute infectious syndromes to management of ambulatory patients with acute or chronic infections; ho

79 data on 80 clinical characteristics from 268 ambulatory patients with advanced heart failure (derivat

80 ology, trajectories, and therapies for other ambulatory patients with advanced HF are poorly understo

81 INTERMACS profiles help identify ambulatory patients with advanced HF who may benefit fro

82 etween noncardiac comorbidities and HRQOL in ambulatory patients with advanced HF.

83 palliative and oncology care is feasible in ambulatory patients with advanced NSCLC.

84 Ambulatory patients with advanced urothelial carcinoma w

85 vular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not bee

86 In a large, contemporary cohort of ambulatory patients with atrial fibrillation who receive

87 -blind, randomized trial involving high-risk ambulatory patients with cancer (Khorana score of >=2, o

88 Prophylaxis is not currently recommended for ambulatory patients with cancer (with exceptions) or for

89 reported on DOACs for thromboprophylaxis in ambulatory patients with cancer at increased risk of VTE

90 In this study, 25% of ambulatory patients with cancer lacked protective antibo

91 .5 mg twice daily) for thromboprophylaxis in ambulatory patients with cancer who were at intermediate

92 did placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemot

93 Ambulatory patients with cancer, aged 18 years or older,

94 In high-risk ambulatory patients with cancer, treatment with rivaroxa

95 diagnose narcolepsy might be most useful in ambulatory patients with cataplexy but with a normal mul

96 used to further prognostically risk stratify ambulatory patients with CHF referred for heart transpla

97 independently predicts adverse prognosis in ambulatory patients with CHF.

98 be used as a disease-specific instrument in ambulatory patients with cholestatic liver disease.

99 of discontinuation of digoxin on outcomes in ambulatory patients with chronic heart failure (HF) with

100 ted at any time during clinical follow-up in ambulatory patients with chronic heart failure are highl

101 imal treadmill exercise were measured in 185 ambulatory patients with chronic heart failure who had b

102 provide important prognostic information in ambulatory patients with chronic heart failure with syst

103 ristics and long-term prognosis of anemia in ambulatory patients with chronic heart failure.

104 prevalence and relationship to prognosis in ambulatory patients with chronic HF.

105 In ambulatory patients with chronic mild to moderate diasto

106 A total of 126 ambulatory patients with chronic renal failure treated w

107 f cardiac troponin I (cTnI) in asymptomatic, ambulatory patients with chronic renal failure treated w

108 We followed up 558 consecutive ambulatory patients with chronic, stable systolic HF (le

109 Pre-LT cohort included ambulatory patients with cirrhosis awaiting LT, without

110 Nineteen ambulatory patients with clinically active disease were

111 (CrCl) in relation to 6-min walk distance in ambulatory patients with congestive heart failure (HF).

112 prognostic accuracy of identifying high risk ambulatory patients with congestive heart failure consid

113 In ambulatory patients with congestive HF, estimated CrCl p

114 Among ambulatory patients with coronary artery disease or CHF,

115 Ambulatory patients with COVID-19 who received bamlanivi

116 The COLCORONA trial included ambulatory patients with COVID-19 with at least 1 high-r

117 specific (S-RBD-specific) MBCs in cohorts of ambulatory patients with COVID-19 with mild disease (n =

118 world, retrospective study of 403 high-risk, ambulatory patients with COVID-19, receipt of bamlanivim

119 thiazolidinedione (TZD) use and outcomes in ambulatory patients with diabetes and heart failure (HF)

120 Herein, we report real-world data of 11 ambulatory patients with DMD, ages 4-6, treated with com

121 marker concentrations were ascertained in 86 ambulatory patients with established heart failure.

122 In ambulatory patients with established HF and diabetes, th

123 ICG) in predicting clinical deterioration in ambulatory patients with heart failure (HF).

124 e of risk prediction models for mortality in ambulatory patients with heart failure and describe thei

125 Ambulatory patients with heart failure tended to substan

126 stimate more than 50% 1-year mortality among ambulatory patients with heart failure who die in the su

127 nformation that can be used to risk stratify ambulatory patients with heart failure with ischemic or

128 death declined substantially over time among ambulatory patients with heart failure with reduced ejec

129 double-blind, randomized trial, we assigned ambulatory patients with heart failure, a left ventricul

130 luable independent prognostic information in ambulatory patients with heart failure.

131 ssess heart transplantation (HTx) urgency in ambulatory patients with heart failure.

132 stem provides additional risk information in ambulatory patients with heart failure.

133 ed with outcomes in a well-treated cohort of ambulatory patients with HF although it did not signific

134 thesized that mode of death differs by EF in ambulatory patients with HF and preserved left ventricul

135 es have described BP and glycemic control in ambulatory patients with HF and racial and ethnic dispar

136 -controlled, randomized trial, enrolled 6105 ambulatory patients with HF and reduced ejection fractio

137 lacebo-controlled randomized trial, eligible ambulatory patients with HF and reduced LVEF were recrui

138 In ambulatory patients with HF and reduced LVEF, thiamin su

139 and metabolism) by gas chromatography in 905 ambulatory patients with HF caused by different etiologi

140 dy found that SGLT2i use had increased among ambulatory patients with HF during the study period, the

141 d long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failur

142 modified sandwich immunoassay in consecutive ambulatory patients with HF who were followed up for 4.1

143 etected during routine clinical follow-up of ambulatory patients with HF, are highly associated with

144 s have dramatically improved the survival of ambulatory patients with HF, outcomes for patients with

145 e technology in the functional assessment of ambulatory patients with HF.

146 The study enrolled 1,310 ambulatory patients with HFrEF from April to October 202

147 ed trial testing the effect of vericiguat in ambulatory patients with HFrEF who had not experienced r

148 e as an initial prognostic screening tool in ambulatory patients with impaired systolic function who

149 Despite proven benefit in ambulatory patients with ischemic heart disease, the pat

150 Our population consisted of ambulatory patients with laboratory-confirmed influenza

151 mmune suppressive therapy and HSC support in ambulatory patients with less accumulated disability and

152 anticoagulants (rivaroxaban or apixaban) in ambulatory patients with locally advanced or metastatic

153 patients with HD screened for the study, 37 ambulatory patients with manifest HD (mean [SD] age, 52.

154 f of headache in approximately 55 percent of ambulatory patients with migraine.

155 ndomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who w

156 nt consensus guidelines for the treatment of ambulatory patients with mild to severe active UC.

157 Forty-five ambulatory patients with MS (34 women, 11 men) and 25 se

158 High-risk ambulatory patients with New York Heart Association clas

159 ilure, to assess the mode of death in 10,538 ambulatory patients with New York Heart Association clas

160 reported outcomes and end-of-life care among ambulatory patients with newly diagnosed disease.

161 These ambulatory patients with newly diagnosed HIV infection,

162 Ambulatory patients with no visceral metastases and more

163 referred to as "hospitalized" patients), (2) ambulatory patients with noncholestatic cirrhosis, (3) p

164 Ambulatory patients with NSCLC, aged 75 years or younger

165 rocardiographic databases to identify 13 559 ambulatory patients with NVAF from July 1996 through Dec

166 ffered as the first-line treatment to stable ambulatory patients with OHS and coexistent severe obstr

167 strongly suspected of having OHS, 2) stable ambulatory patients with OHS receive positive airway pre

168 urological disease (1.0+/-0.9) controls, and ambulatory patients with Parkinson's disease (1.8+/-1.1)

169 A total of 75 consecutive ambulatory patients with persistent advanced heart failu

170 The need for heart transplantation in ambulatory patients with severe heart failure is better

171 icoagulants with placebo or standard care in ambulatory patients with solid tumours and no indication

172 ve advanced malignant conditions, and 90% of ambulatory patients with spinal cord compression can rem

173 We prospectively studied 15 ambulatory patients with stable coronary disease who wer

174 strong predictor of cardiovascular events in ambulatory patients with stable coronary heart disease a

175 veillance without anticoagulation for select ambulatory patients with subsegmental pulmonary embolism

176 rric carboxymaltose, added to usual care, in ambulatory patients with symptomatic HF with reduced eje

177 important measures of functional capacity in ambulatory patients with symptomatic HFrEF.

178 iation exposure and cost of care in low-risk ambulatory patients with symptoms of acute coronary synd

179 Ambulatory patients with systolic HF, a heavy symptom bu

180 nd newly diagnosed tuberculosis (hereafter, "ambulatory patients with tuberculosis"), and 58 ambulato

181 mong hospitalized patients, 19.1 ng/mL among ambulatory patients with tuberculosis, and 5.9 ng/mL amo

182 ients with tuberculosis, and 5.9 ng/mL among ambulatory patients without tuberculosis (P < .001).

183 ection and without tuberculosis (hereafter, "ambulatory patients without tuberculosis").

184 Ambulatory patients wore eye tracking glasses for up to